iqvia weight loss drug prescriptions q3 2024 semaglutide tirzepatide The weight-loss boom has created massive market opportunities — and punishing failures. In this space, a single clinical trial result can send a stock soaring or instantly wipe out years of gains iqvia semaglutide tirzepatide prescriptions q3

This medication can help treat medical conditions such as type 2 diabetes (T2D), obesity, and non-alcoholic fatty liver disease

The results demonstrated that the protein expression of acyl-CoA synthetase long-chain family member 4 (ACSL4) NOX4 and COX2 got markedly elevated, while the GPX4 and FTH levels were overtly reduced in TPC-1-Lv-FTO compared with that of the vector group

Blaszczak, A

In the ExA study, the METH intake after an acute treatment was 5.41 1.05 mg/kg in control and 4.72 0.71 mg/kg in LIR-treated rats (t-test, p = 0.625)

The first head-to-head clinical trial (SURMOUNT-5, published in NEJM 2025) showed tirzepatide produced 20.2% average weight loss at 72 weeks versus 13.7% for semaglutide approximately 47% greater relative weight loss